CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

SteroidAdvancedHigh Risk

Prostanozol

Also known as: Demethylstanozolol THP ether, Prostanozol

Prostanozol is a designer steroid that is a modified form of stanozolol. It was marketed as a dietary supplement prohormone that converts to stanozolol in the body. It was subsequently classified as an anabolic steroid and banned. Extremely limited research exists on this compound.

Evidence10/100 — Minimal

Risk Level

High Risk

Difficulty

Advanced
Molecular FormulaC25H40N2O2
ClassSteroid
CategoryUnderground Steroids

Mechanism of Action

Acts as a prodrug that is believed to convert to stanozolol or a stanozolol-like metabolite after oral administration. The THP ether group is cleaved during first-pass metabolism. Theoretically provides the same mechanism of action as stanozolol once converted, though conversion efficiency is unknown.

Dosing Research

No clinically established dosing. Was previously marketed as a supplement at doses of 50-100 mg per day. Cycle lengths were typically 4-6 weeks. Effectiveness and conversion rates are poorly documented. Requires PCT after use.

Side Effects & Risks

Expected to carry similar risks to stanozolol if conversion occurs, including hepatotoxicity, lipid profile deterioration, and joint dryness. Additional unknown risks due to the prodrug mechanism and uncertain metabolic pathway. No formal safety data available.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ